OnKure Therapeutics
OKUR
39 hedge funds and large institutions have $149M invested in OnKure Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 3 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
9% more capital invested
Capital invested by funds: $137M → $149M (+$12.2M)
3% more funds holding
Funds holding: 38 → 39 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.94% less ownership
Funds ownership: 75.25% → 71.31% (-3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$184K |
| 2 |
BlackRock
New York
|
+$166K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$111K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$99K |
| 5 |
PCM
Pinz Capital Management
New York
|
+$67.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.33M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.11M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$464K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$74.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.5K |
OKUR Hedge Fund Activity: Q4 2021 in Review
39 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2021, worth a combined $149M — up 8.9% from $137M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new OKUR positions and 3 closed out — a net gain of 2 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $184K. The largest seller was Deerfield Management, exiting entirely with an estimated $6.33M sold.
- 39 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2021, up from 38 in Q3 2021.
- Funds reported $149M of OnKure Therapeutics stock for Q4 2021, up 8.9% quarter-over-quarter.
- 5 funds opened new OnKure Therapeutics positions in Q4 2021 and 3 closed out, a net change of +2 holders.
- The largest OnKure Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $184K added.
- The largest OnKure Therapeutics seller in Q4 2021 was Deerfield Management, an estimated $6.33M sold.
Based on aggregated 13F filings for Q4 2021.